Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization

Nian Liu,JiangLin Zhang,Mingzhu Yin,Hong Liu,Xu Zhang,Jiaoduan Li,Bei Yan,Yeye Guo,Jianda Zhou,Juan Tao,Shuo Hu,Xiang Chen,Cong Peng

DOI: https://doi.org/10.1016/j.ymthe.2021.03.013

IF: 12.91

2021-07-01

Molecular Therapy

Abstract:<p>Tumor cells increase glutamate release through the cystine/glutamate transporter xCT to balance oxidative homeostasis in tumor cells and promote tumor progression. Although clinical studies have shown the potential of targeting PD-1/PD-L1 signaling in melanoma, response rates are low. However, it remains unclear how glutamate metabolism affects anti-PD-1/PD-L1 treatment efficacy in melanoma. Here, we demonstrated that although inhibition of xCT either by pharmacological inhibitor (sulfasalazine, SAS), approved by FDA for inflammatory diseases, or genetic knockdown induced ROS-related death in melanoma cells, inhibition of xCT significantly reduced the efficacy of anti-PD-1/PD-L1 immune checkpoint blockade through upregulating PD-L1 expression via the transcription factors IRF4/EGR1, as a consequence, exosomes carrying relatively large amounts of PD-L1 secreted from melanoma cells resulted in M2 macrophage polarization and, reduced the efficacy of anti-PD-1/anti-PD-L1 therapy in melanoma. Taken together, our results reveal that inhibition of xCT by SAS is a promising therapeutic strategy for melanoma, on the other hand, SAS treatment blunted the efficacy of anti-PD-1/PD-L1 via exosomal PD-L1 induced macrophage M2 polarization, and eventually induced anti-PD-1/PD-L1 therapy resistance.</p>

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology